Lung Cancer
A Randomized, Open-Label, Phase 3 Study of Pralsetinib versus Standard of Care for First Line Treatment of RET fusion-positive, Metastatic Non-Small Cell Lung Cancer (BLU-667-2303)
- Details
ClinicalTrials.gov ID:
NCT04222972
Diagnosis Type:
NA
USOR Number:
- Address
603 N Wilmot Rd, Suite 151
Tucson, AZ 85711
P: (520) 886-0206